Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
verywellhealth9h
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
GlobalData on MSN21h
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...
Ozempic Could Prevent Diabetes. Should It Be Used for That?
New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...
Hosted on MSN2d
What Role Do Peptides Play in Weight Loss?
These medications attach to specific sites on certain cells ... In late 2023, the FDA approved Zepbound (tirzepatide), a weekly injection, for weight loss in adults. Unlike other weight-loss ...
Weight Loss Injections: What You Need to Know, From Costs to Alternatives
Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...